Unknown PHASE1 INTERVENTIONAL 1-arm NCT03281551

Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma

Study of Anti-CD19 Chimeric Antigen Receptor T Cells（PZ01） for Relapsed/ Refractory B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma

Sponsor: Chinese Academy of Sciences

Conditions B-cell Acute Lymphoblastic Leukemia B-cell Lymphoma

Interventions PZ01 CAR-T cells

Updated 6 times since 2017 Last updated: Sep 14, 2017 Started: Oct 1, 2017 Primary completion: Sep 1, 2020 Completion: Nov 1, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoma, this trial is ongoing. The trial is conducted by Chinese Academy of Sciences and has accumulated 6 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Dec 2020 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jun 2018 — Dec 2020 [monthly]

Recruiting PHASE1

▶ Show 1 earlier version

Oct 2017 — Jun 2018 [monthly]

Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese Academy of Sciences
Navy General Hospital, Beijing
Pinze Lifetechnology Co. Ltd.

Data source: Pinze Lifetechnology Co. Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China